Plus: Medtronic Extended-Wear Infusion Set & more from ADA 2021
Tuesday, July 13, 2021 : Issue #1149 |
|
Letter from the Editor
The recent ADA Scientific Sessions have been chock full of great information. It appears as if the Pandemic had no effect on research of devices and medications.
There was a lot of focus on the SGLT-2 Inhibitors and the multiple positive effects for diabetes patients. This week our intern, Alan Martinez from USF College of Pharmacy, looked at the research on the use of these medications to prevent the metabolic complications of the coronavirus. Check out the results by clicking here.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
Newsflash: FDA Approves Drug for Adults with Chronic Kidney Disease Associated with Type 2 Diabetes
The US Food and Drug Administration (FDA) approved finerenone (Kerendia), the first agent from a new class of nonsteroidal mineralocorticoid receptor antagonists (MRAs), on July 9 for treating patients with chronic kidney disease (CKD) associated with type 2 diabetes. |
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| | | | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
